|
|
|
|
Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110
| |
Summary |
|---|
|
|
|---|
Aspirin and aspirin-like drugs are the most commonly indicated agents
for the treatment of inflammation. Mechanisms of action for these
drugs, however, are not clearly understood. In this study, we examined
the effects of aspirin on production of nitric oxide (NO), a
proinflammatory mediator, and show that aspirin inhibits NO production
by transformed pancreatic
cells (RINm5F) and rat islets in a
concentration-dependent manner with an IC50 value of ~3
mM. Therapeutic concentrations of aspirin (1-5
mM) that block NO production affected neither nuclear
factor-
B activation nor inducible NO synthase (iNOS) mRNA
transcription but potently inhibited iNOS protein expression by both
RINm5F cells and rat islets. The effects of aspirin on islet function
were examined by measuring glucose-stimulated insulin secretion in the
presence of various concentrations of aspirin. Aspirin (1-5
mM) did not affect insulin secretion at basal or
glucose-stimulated conditions, whereas higher concentrations of aspirin
(10-20 mM) significantly increased basal insulin
secretion. Aspirin at high concentrations of 10 and 20 mM
inhibited de novo protein synthesis as demonstrated by
inhibition of [35S]methionine incorporation into total
islet protein and by inhibition of rabbit reticulocyte expression by
Brome mosaic virus mRNA, suggesting that inhibition of iNOS expression
at these high concentrations of aspirin may be due to the impairment of
the translational machinery. These findings indicate that inhibition of
iNOS expression and NO production may explain, in part, the beneficial
effects of aspirin as an anti-inflammatory agent at therapeutic
concentrations, whereas inhibition of de novo protein
synthesis may possibly explain clinical and side effects of aspirin in
the inflamed tissues and organs such as stomach and kidney that may
accumulate high concentrations of aspirin.
| |
Introduction |
|---|
|
|
|---|
Aspirin
and ALD are the most commonly indicated agents for treatment of
inflammation. These drugs have an enormous range of effects, including
reducing pain or fever, dissolving corns, inhibiting blood clotting,
inducing peptic ulcers, and promoting uric acid loss and fluid
retention by the kidneys (1). The broad range of biological actions of
aspirin have made it difficult to delineate its mechanisms of action.
The most well accepted mechanism of action of aspirin is inhibition of
prostaglandin biosynthesis (2). This theory, however, has been
challenged because of discrepancies in clinical efficacies of aspirin
in the treatment of diseases such as rheumatic fever, gout, and
rheumatoid arthritis, which require much higher doses of aspirin (4-8
g/day) than required to inhibit prostaglandin production (1, 3).
Moreover, salicylic acid, which is ineffective as a prostaglandin H
synthase inhibitor, is nevertheless able to reduce inflammation at
comparable doses to aspirin (1, 3). As alternative mechanisms of action
for aspirin and ALD, the interference of cellular signaling by binding to key regulatory proteins such as G proteins (1) and inhibition of the
transcriptional factor NF-
B (3) have been proposed. Nonspecific
effects of aspirin and ALD due to high concentrations accumulated in
some organs have also been proposed to account for the clinical and
side effects of these drugs (4).
NO synthesized by iNOS has been implicated as a mediator of
inflammation in rheumatic and autoimmune diseases (5-7). We (8-10) and others (11-13) have previously shown that cytokine-mediated production of NO by pancreatic
cells plays a key role in
dysfunction and destruction of
cells associated with autoimmune
diabetes. In light of the possible role of NO in the pathogenesis of
autoimmune diabetes, we sought to find agents that block NO production
by pancreatic
cells. In this study, we report that aspirin blocks NO production by primary and transformed rat pancreatic
cells at
therapeutic concentrations and inhibits total de novo
protein synthesis at higher concentrations, which may explain some of the clinical and toxic effects of aspirin.
| |
Materials and Methods |
|---|
|
|
|---|
Male Sprague-Dawley rats (160-180 g) were purchased from Sasco
(O'Fallon, MO). Collagenase type P was obtained from
Boehringer-Mannheim Biochemicals (Indianapolis, IN). Tissue culture
medium (CMRL-1066), penicillin, streptomycin, Hanks' balanced salt
solution, heat-inactivated fetal bovine serum, and
L-glutamine were obtained from GIBCO (Grand Island, NY).
The insulinoma cell line RINm5F was obtained from the Washington
University Tissue Culture Support Center (St. Louis, MO). NMMA acetate
was purchased from Calbiochem (San Diego, CA). Acetylsalicylic acid
(solubilized in complete CMRL supplemented with 20 mM
HEPES, pH 7.4), Na salicylate, and indomethacin were from Sigma
Chemical (St. Louis, MO). IL-1
was from Cistron Biotechnology (Pine Brook, NJ). The cDNA probe for iNOS was a gift from Dr. Charles
Rodi (Monsanto, St. Louis, MO), and the cDNA probe for cyclophilin was
a gift from Dr. Jeffrey Milbrandt (Washington University).
[
-32P]dCTP was obtained from Amersham
(Arlington Heights, IL). Oligonucleotide labeling kits were from
Pharmacia (Piscataway, NJ). The
35S-trans-labeled methionine (117 Ci/mmol) was from ICN (Costa Mesa, CA), and antisera to iNOS were
obtained from Dr. Michael Marletta (University of Michigan, Ann Arbor)
and Alexis Biochemicals (San Diego, CA). NF-
B consensus
oligonucleotides
(5
-GATCCGAGGGGACTTTCCGCTGGGGACTTTCC-AGG-3
) and T4 polynucleotide kinase were obtained from Oncogene Science (Uniondale, NY). In vitro translation kits were obtained
from Amersham Life Science (Buckinghamshire, UK).
Preparation of islets. Islets were isolated from male Sprague-Dawley rats by collagenase digestion as previously described (14). Briefly, on the day before each experiment, each pancreas was inflated with Hanks' balanced salt solution, and the tissue was isolated, minced, and digested with 6 mg of collagenase/pancreas for 9 min at 39°. Islets were separated on a Ficoll step-density gradient and then selected with a stereomicroscope to exclude any contaminating tissues. Islets (1200-1500) were then cultured overnight under an atmosphere of 95% air/5% CO2 at 37° in 3 ml of complete CMRL-1066 media [CMRL-1066 containing 2 mM L-glutamine, 5.5 mM D-glucose, 10% (v/v) heat-inactivated fetal bovine serum, 100 units of penicillin/ml, and 100 µg of streptomycin/ml].
Nitrite determination.
RINm5F cells (2 × 105) were cultured at 37° for 24 hr in 200 µl
of complete CMRL-1066 supplemented with 20 mM HEPES, pH
7.4, in the presence and absence of IL-1
(10 units/ml) and various concentrations of aspirin or Na salicylate as indicated in the figure
legends. The culture supernatant was removed, and 50-µl aliquots were
mixed with 50 µl of Griess reagent (15). Nitrite production was
determined at an absorbance of 540 nm using a Titertek Multiskan
MCC/340 plate reader.
Nuclear extract preparation and electrophoretic mobility shift
analysis.
Cytosolic and nuclear proteins were isolated from RINm5F
cell monolayers according to the method of Flanagan et al.
(16) Cytosolic and nuclear proteins were stored frozen at
70°
before assay, and protein concentration was determined using a
micro-BCA kit (Pierce, Rockford, IL). Double-stranded synthetic
oligonucleotide probes for NF-
B were end-labeled with
[
-32P]ATP and T4 polynucleotide kinase.
Cytosolic and nuclear proteins (10 µg) were incubated with
oligonucleotide probes (60,000 cpm) for 35 min at room temperature, and
protein/DNA complexes were resolved by polyacrylamide gel
electrophoresis (17).
RNA isolation and Northern blot analysis.
RINm5F cells
(5-7 × 107) or islets (1500) were treated
with IL-1
for the indicated time periods as shown in the figure
legends, followed by washing three times with PBS, pH 7.4, and then
solubilization in 3.5 ml of 4 M guanidinium isothiocyanate.
Total RNA from lysates was sedimented by ultracentrifugation on a
cushion of 5.7 M cesium chloride (18). Total cellular RNA
(20-50 µg) was denatured and fractionated electrophoretically using
a 1.2% agarose gel containing 3% formaldehyde and transferred by
blotting to nylon membranes. Blots were prehybridized overnight at
42° with prehybridization buffer (19). Hybridization was carried out
overnight at 42° in fresh prehybridization buffer containing
32P-labeled cDNA probes. cDNA probes were labeled
with [
-32P]dCTP using a nick-translation kit
according to the supplier's (Pharmacia) instructions. After
hybridization, the membranes were extensively washed with buffer
[0.1% SDS and 0.1× standard saline citrate (0.15 M NaCl,
0.015 M sodium citrate, pH 7.0)] at 42° and
autoradiographed with intensifying screens at
70°.
Determination of iNOS protein expression.
RINm5F cells
(5 × 105 in 500 µl complete CMRL-1066
supplemented with 20 mM HEPES) were activated with 10 units/ml IL-1
and various concentrations of aspirin (1-20
mM) for 24 hr. Cells were washed three times with PBS, pH
7.4, and solubilized in Laemmli's sample buffer (30 µl). Samples
were denatured, run on a 10% SDS acrylamide gel, and transferred to
Hybond ECL Nitrocellulose (Amersham) and immunoblot analysis was
performed using rabbit iNOS antiserum (1:2000) and
peroxidase-conjugated donkey anti-rabbit IgG (1:7000) as the primary
and the secondary antisera, respectively. Proteins were detected by
enhanced chemiluminescence (ECL; Amersham). iNOS protein expression by
rat islets was determined by immunoprecipitation of iNOS from
metabolically labeled rat pancreatic islets as previously described
(20). Briefly, islets (200 in 500 µl of complete CMRL-1066) were
washed three times with 500 µl of methionine-deficient MEM (9 parts
MEM without methionine/1 part MEM containing methionine) supplemented
with 20 mM HEPES (pH 7.4) and incubated at 37° for 5 hr.
Islets were then treated with 5 units/ml IL-1
, various concentrations of aspirin (1-20 mM), and 215 µCi of
[35S]methionine Trans-Label (ICN)
and further incubated for 19 hr. Islets were then isolated by
centrifugation (20 sec at 14,000 rpm), washed, and processed for
immunoprecipitation of iNOS using a rabbit affinity-purified polyclonal
antibody raised against a peptide corresponding to mouse macrophage
amino acid residues 1131-1144 according to the modified method of
Corbett et al. (21).
Glucose-stimulated insulin secretion. Isolated islets (150/1 ml of complete CMRL-1066 supplemented with 20 mM HEPES, pH 7.4, to avoid changes in pH due to high concentrations of aspirin) were exposed to various concentrations of aspirin (1-20 mM) for 24 hr at 37°. After the exposure, islets were washed three times (1 ml/wash) in KRB buffer (containing 25 mM HEPES, 115 mM NaCl, 24 mM NaHCO3, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, pH 7.4) containing 3 mM D-glucose and 0.1% bovine serum albumin. Groups of 20 islets were counted into 10 × 75-mm siliconized borosilicate tubes and preincubated for 30 min in 200 µl of the same buffer under an atmosphere of 95% air/5% CO2 at 37° with shaking. The preincubation buffer was removed, and glucose-stimulated insulin secretion was initiated by the addition of 200 µl of fresh KRB containing either 3 or 20 mM D-glucose followed by a 30-min incubation. Insulin secretion was determined in the incubation buffer by insulin radioimmunoassay.
[35S]Methionine incorporation into rat islets. Isolated rat islets (100) were cultured at 37° for 24 hr in 1 ml of complete CMRL-1066 supplemented with 20 mM HEPES in the presence of 10 µM cycloheximide or the indicated concentrations of aspirin. [35S]Methionine (14.3 µCi/µl) was included in all samples. After the 24-hr culture period, the islets were distributed (20 islets/tube) into 1.5-ml polyallomer tubes. The islets were washed three times with fresh CMRL-1066 medium to remove unincorporated radiolabel. Then, 500 µl of ice-cold TCA (10% w/v) was added to precipitate islet protein. The islets were sequentially washed and pelleted three times with the ice-cold TCA solution. The 35S content of the pellet was then determined by liquid scintillation counting (model 1500; Packard Instruments, Downers Grove, IL).
In vitro translation of BMV mRNA. Translational reactions (final, 50 µl), including biotin-Lys-tRNA (1 µl) and rabbit reticulocyte lysate (20 µl), were prepared following the manufacturer's instructions (Amersham Life Science). Increasing concentrations of aspirin (1-20 mM) were added to the reaction mixtures and incubated at 30° for 1 hr, and the reaction was terminated by placing the samples on ice. Samples were denatured, run on a 10% SDS acrylamide gel, and transferred to Hybond ECL Nitrocellulose. Blots were blocked for 1 hr at room temperature in 5% blocking agent (included in the kit) in PBS-T (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20), followed by incubation in 10 ml of PBS-T containing the streptavidin-horseradish peroxidase conjugate (1:1000 dilution). Four different proteins encoded by BMV virus mRNA were detected by ECL.
Statistics. Statistical comparisons were made between groups using a one-way analysis of variance. Significant differences (p < 0.05) were evaluated using Scheffé F test post hoc analysis.
| |
Results |
|---|
|
|
|---|
Aspirin inhibited IL-1
-induced production of nitrite, an
oxidized form of NO, by the insulinoma cell line RINm5F in a
concentration-dependent manner with an IC50 value
of ~3 mM (Fig. 1,
black bars). The NOS inhibitor NMMA (0.5 mM)
also inhibited IL-1
-induced nitrite production to control levels,
and aspirin in the absence of IL-1
had no effect on nitrite levels
(data not shown). The same dose-dependent effects of aspirin on
IL-1
-induced production of nitrite were observed with isolated rat
islets (Table 1). The acetyl moiety of
aspirin (acetylsalicylate) does not seem to be required for the
inhibition of nitrite generation because Na salicylate exhibits a
similar concentration-dependent inhibition of nitrite production by
RINm5F cells compared with aspirin (Fig. 1, hatched
bars). Indomethacin (1-100 µM), another
nonsteroidal anti-inflammatory drug, which is structurally dissimilar
to aspirin, had no effect on IL-1
-induced nitrite formation (Table
2), suggesting that the ability of
aspirin to block IL-1
-induced nitrite formation may be unique among
nonsteroidal anti-inflammatory drugs.
|
|
|
Because NF-
B is a primary transcriptional factor in the regulation
of iNOS (22, 23), we initially examined the effects of aspirin at
therapeutic concentrations (1-5 mM) on IL-1
-induced NF-
B activation. Aspirin (1-5 mM) did not inhibit
IL-1
-induced translocation of NF-
B to the nucleus of RINm5F cells
(Fig. 2A, lanes 9 and 10),
whereas high concentrations of aspirin (10-20 mM)
significantly blocked NF-
B translocation (Fig. 2A, lanes 11 and 12). Cytosolic proteins isolated in parallel with the nuclear proteins did not form protein/DNA complexes (Fig. 2A, lanes
1-6). The addition of an excess amount (150-fold) of unlabeled
NF-
B oligonucleotides to the reaction mixture prevented the
appearance of the NF-
B band (Fig. 2B, lane 2). Supershift
assays using antibodies for NF-
B subunits p50 and p65 resulted in
the complexes at the top of the gels being retained (Fig. 2B,
lanes 3 and 4). Antibodies for c-Jun and
c-Fos, however, did not affect the migration of the NF-
B
band (Fig. 2B, lanes 5 and 6). These results suggest that
the site of action of aspirin (1-5 mM) to block NO
formation is not at the level of NF-
B activation.
|
To determine whether aspirin inhibits NO production at the level of
transcription, we next examined the effects of aspirin on
IL-1
-induced iNOS mRNA transcription by RINm5F cells and rat islets
using Northern blot analysis. Aspirin (1-10 mM) did not inhibit IL-1
-induced iNOS mRNA expression by both RINm5F cells and
rat islets (Fig. 3, top and
bottom). However, 20 mM aspirin completely
blocked iNOS mRNA expression by RINm5F cells (Fig. 3, top,
first blot, lane 6). Complete inhibition of iNOS
mRNA transcription in the presence of 20 mM aspirin may be
due to nonspecific or cytotoxic effects of aspirin as reflected by
increased basal insulin secretion (see Fig. 7). Transcriptional
machinery, however, seems to be intact in the presence of 20 mM aspirin because cyclophilin mRNA is minimally affected
(Fig. 3, top, second blot, lane 6). These experiments suggest that aspirin (1-10 mM) does not
affect iNOS transcription by RINm5F cells and rat islets determined
after a 6-hr exposure to IL-1
and aspirin.
|
|
To examine whether aspirin down-regulates iNOS mRNA expression by
decreasing its half-life, which might be detectable at a later time
point, we examined the effects of aspirin on the time course of iNOS
mRNA expression by RINm5F cells. We have previously demonstrated that
IL-1
-induced iNOS mRNA expression by RINm5F cells is detectable
after 3 hr, peaks at ~6 hr, and decreases significantly after a 9-hr
exposure to IL-1
(24). Therefore, we examined the 0-, 6-, and 9-hr
time points. Aspirin (5 and 10 mM) did not affect iNOS mRNA
expression after a 6-hr exposure (Fig.
4A, lanes 3-5), confirming
our results shown in Fig. 3. However, aspirin increased the levels of
iNOS mRNA in a concentration-dependent manner (Fig. 4A, compare
lane 6 with lanes 7 and 8) determined after a
9-hr exposure to IL-1
and aspirin, suggesting that aspirin increases
the steady state levels of iNOS mRNA. Fig. 4B shows quantification of
iNOS mRNA expression by laser densitometry, normalized by calculating
the ratio of iNOS over cyclophilin. iNOS mRNA expression by the group
treated with IL-1
and 10 mM aspirin for 9 hr
(eighth bar) is significantly increased compared with the
control group (sixth bar).
|
Because aspirin (1-5 mM) did not affect iNOS mRNA
transcription, the effects of aspirin on iNOS protein expression by
RINm5F cells and rat islets were examined by Western blot analysis and immunoprecipitation, respectively. As shown in Fig.
5, A and B, aspirin inhibits
IL-1
-induced iNOS protein expression in a concentration-dependent manner by both RINm5F cells and rat islets, similar to the inhibitory effects of aspirin on nitrite formation. Significant inhibition of iNOS
expression is observed at 3 and 5 mM aspirin (Fig. 5, A and
B, lanes 4 and 5), and complete inhibition is observed at 20 mM aspirin (Fig. 5, A and B, lane 7) after a
24-hr exposure to IL-1
. Fig. 6, A and
B, shows quantification of iNOS protein expression by the two cell
types by laser densitometry. These results suggest that aspirin (1-5
mM) blocks NO formation at the level of protein synthesis.
|
|
To determine whether the inhibitory effects of aspirin on iNOS
expression are due to the cytotoxic effects of aspirin caused by its
high concentration, we examined the effects of aspirin on islet
function by measuring glucose-stimulated insulin secretion from
isolated rat islets. Because IL-1
by itself inhibits
glucose-stimulated insulin secretion by rat islets, we did not include
IL-1
for these experiments. Aspirin (1-5 mM) did not
affect insulin secretion at basal or glucose-stimulated conditions,
whereas higher concentrations of aspirin (10-20 mM)
significantly increased basal insulin secretion (Fig.
7). These results indicate that aspirin
at high concentrations has deleterious effects on islet function. Thus,
the inhibition of NO formation at these high concentrations (10-20
mM) may be due to cytotoxic effects.
Because high concentrations of aspirin had deleterious effects on islet function, we examined the effects of aspirin on cell viability by trypan blue dye exclusion and total protein synthesis by [35S]methionine incorporation into rat islets. Incubation of RINm5F cells for 24 hr in the presence of 10 and 20 mM aspirin did not affect cell viability based on trypan blue dye exclusion experiments (data not shown). These concentrations of aspirin, however, significantly inhibited total de novo protein synthesis to a level in the case of 20 mM aspirin comparable to cycloheximide (10 µM), as shown in Fig. 8. Therapeutic concentrations of aspirin (1-5 mM) that inhibited iNOS protein expression did not block total protein synthesis. Although 5 mM aspirin decreased protein synthesis, this effect was not statistically significant. Similar results were obtained with RINm5F cells and RAW 264.7 cells (data not shown).
|
Next, we examined whether the inhibition of total de novo protein synthesis by aspirin at the concentrations of 10 and 20 mM is due to the impairment of the translational machinery by studying the effects of aspirin on in vitro translation of BMV mRNA. As shown in Fig. 9, aspirin (10-20 mM) inhibited the translation of four BMV viral mRNAs coding for proteins with molecular masses of 109, 94, 35, and 20 kDa using a rabbit reticulocyte lysate system. Aspirin (1-5 mM) did not inhibit the translation of the viral mRNAs, supporting the results shown in Fig. 8. The two higher molecular mass proteins, 109 and 94 kDa, are reported to often run as one band (manufacturer's instruction manual), as indicated in Fig. 9 (110/97). Exclusion of the BMV mRNA or incubation with cycloheximide (10 µM) completely prevents protein synthesis (Fig. 9, lanes 1 and 3, respectively). These experiments suggest that aspirin at 10 and 20 mM concentrations impair the translational machinery. Therefore, the inhibition of iNOS expression under these high concentrations may be, in part, due to its impairment of the translational machinery in RINm5F cells and rat islets.
|
| |
Discussion |
|---|
|
|
|---|
In this study, we report that aspirin at therapeutic
concentrations (1-5 mM) inhibits NO production at the
level of iNOS protein expression by RINm5F cells and rat islets. Higher
concentrations of aspirin (10-20 mM) stimulated basal
insulin secretion and inhibited NF-
B activation, iNOS mRNA
transcription, and total de novo protein synthesis.
Inhibition of NO production by islets at therapeutic concentrations of
aspirin suggests that this may explain the beneficial effects of
aspirin as an anti-inflammatory agent.
Although total de novo protein synthesis is greatly reduced
at high concentrations of aspirin (10-20 mM), cells seem
to be intact functionally based on several observations: (i)
IL-1
-induced NF-
B translocation to the nucleus still occurs,
although at a diminished rate; (ii) cyclophilin mRNA expression is
minimally affected; and (iii) trypan blue exclusion experiments also
suggest that 20 mM aspirin does not affect viability of
these cells (data not shown). Increases in basal insulin secretion,
however, suggest some cytotoxic effects of aspirin at these high
concentrations on cellular function.
The lack of an effect of aspirin on IL-1
-induced iNOS mRNA
expression except at a high concentration of 20 mM (Fig. 4)
is intriguing. Although 10 mM aspirin significantly blocks
(>50%) translocation of NF-
B to the nucleus, this inhibition is
not reflected by reduced iNOS mRNA expression, which is expected
because NF-
B is the primary transcriptional factor in the regulation of iNOS mRNA expression (22, 23). It seems that the level of NF-
B
translocated to the nucleus in the presence of 10 mM aspirin is still sufficient to fully activate the transcription of
iNOS, suggesting that there may exist a threshold level of NF-
B
required for iNOS gene transcription.
The site of action of aspirin or Na salicylate in the signaling pathway
of NO production has been reported to vary among different cell types.
Farivar et al. (25) reported that Na salicylate (4 mM) diminishes steady state levels of iNOS mRNA in neonatal cardiac fibroblasts. On the other hand, Kepka-Lenhart et al.
(26) reported that aspirin (3-10 mM) inhibits
cytokine-induced NO production and expression of iNOS protein without
inhibiting induction of iNOS mRNA in the murine macrophage cell line,
RAW 264.7. Amin et al. (27) also reported that aspirin
(IC50 = 3 mM), but not Na salicylate,
inhibits NO production at the level of iNOS protein expression and also
inhibits enzymatic activity of iNOS in RAW 264.7 cells. In rat islets
and insulinoma RINm5F cells, we report that aspirin (1-5
mM) blocks NO production at the level of iNOS protein
expression without affecting iNOS mRNA levels. Aspirin at higher
concentration (5-10 mM) increases the steady state levels of iNOS mRNA measured after a 9-hr exposure to IL-1
and aspirin (Fig. 4), probably reflecting the accumulation of iNOS mRNA due to the
inhibition of iNOS protein expression at the translational level.
Specific mechanisms by which aspirin inhibits iNOS protein expression by RINm5F cells and rat islets are not clear. High concentrations of aspirin (10-20 mM) seem to inhibit iNOS expression, in part, by impairing the translational machinery based on in vitro translation of BMV mRNA (Fig. 9). However, the mechanisms involved in the inhibition of iNOS expression at lower concentrations of aspirin are currently unknown. Although unlikely, we could not rule out the possibility that iNOS degradation may be accelerated by aspirin.
The results of our current study suggest that relatively high
concentrations of aspirin (10-20 mM) block NF-
B
activation (Fig. 2) and de novo protein synthesis (Figs. 8
and 9). The acidic property of aspirin
(pKa ~ 4) facilitates its cellular
uptake in acidic environments due to increased lipophilicity (4). Therefore, organs that contain acidic compartments, such as stomach, kidney, and inflamed tissues, may attain several-fold higher
concentrations of aspirin compared with plasma levels. Thus, in
vitro studies elucidating various mechanisms of action for aspirin
at high concentrations, including inhibition of NF-
B activation (3),
cellular kinases (28), and de novo protein synthesis
(current study), may be applicable to in vivo situations.
In summary, our results indicate that aspirin at therapeutic
concentrations of 1-5 mM significantly inhibits
IL-1
-induced NO production from both primary and transformed
cells. The primary mechanism responsible for this effect is inhibition
of iNOS protein expression that may be mediated at a
post-transcriptional level by aspirin because neither NF-
B
activation nor iNOS mRNA levels were significantly altered. These
findings may explain, in part, the beneficial effects of aspirin and
aspirin-like drugs when used as anti-inflammatory agents at these
therapeutic concentrations.
| |
Acknowledgments |
|---|
We thank Connie Marshall and Joan Fink for expert technical assistance.
| |
Footnotes |
|---|
Received October 28, 1996; Accepted May 6, 1997
1 Current affiliation: Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St. Louis, MO 63104.
This work was supported by National Institutes of Health Grants DK06181 and T32-DK07296 and a Lucille P. Markey Pathway Postdoctoral Fellowship.
Send reprint requests to: Dr. Michael L. McDaniel, Department of Pathology, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-8118. E-mail: mcdaniel{at}pathology.wustl.edu
| |
Abbreviations |
|---|
ALD, aspirin-like drugs;
IL-1
, interleukin-1
;
NO, nitric oxide;
iNOS, inducible nitric oxide
synthase;
TCA, trichloroacetic acid;
NMMA, NG-monomethyl-L-arginine;
NF-
B, nuclear factor-
B;
BMV, Brome mosaic virus;
PBS, phosphate-buffered
saline;
SDS, sodium dodecyl sulfate;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
MEM, minimum
essential medium;
KRB, Krebs-Ringer-bicarbonate;
ECL, enhanced
chemiluminescence.
| |
References |
|---|
|
|
|---|
| 1. | Weissmann, G. Aspirin. Sci. Am. 264:84-90 (1991)[Medline]. |
| 2. | Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:232-235 (1971)[Medline]. |
| 3. |
Kopp, E. and
S. Ghosh.
Inhibition of NF B by sodium salicylate and aspirin.
Science (Washington D. C.)
265:956-958 (1994) |
| 4. | Brune, K. How aspirin might work: a pharmacokinetic approach. Agents Actions 43:218-220 (1994)[Medline]. |
| 5. | Nathan, C. and Q.-W. Xie. Nitric oxide synthases: roles, tolls, and controls. Cell 78:915-918 (1994)[Medline]. |
| 6. | Schmidt, H. H. and U. Walter. NO at work. Cell 78:919-925 (1994)[Medline]. |
| 7. | Marletta, M. A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78:927-930 (1994)[Medline]. |
| 8. |
Corbett, J. A.,
M. A. Sweetland,
J.-L. Wang,
J. R. Lancaster, and
M. L. McDaniel.
Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans.
Proc. Natl. Acad. Sci. USA
90:1731-1735 (1993) |
| 9. |
Corbett, J. A.,
J. L. Wang, and
T. P. Misko.
Zhao W., W. F. Hickey, and M. L. McDaniel. Nitric oxide mediates IL-1![]() -induced islet dysfunction and destruction: prevention by dexamethasone.
Autoimmunity
15:145-153 (1993)[Medline].
|
| 10. |
Corbett, J. A. and
M. L. McDaniel.
Intraislet release of interleukin-1 inhibits -cell function by inducing cell expression of inducible nitric oxide synthase.
J. Exp. Med.
181:559-568 (1995) |
| 11. | Mandrup-Poulsen, T., S. Helqvist, L. D. Wogensen, J. Molvig, F. Pociot, J. Johannesen, and J. Nerup. Cytokines and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr. Top. Microbiol. Immunol. 164:169-193 (1990)[Medline]. |
| 12. |
Sandler, S.,
D. L. Eizirik,
J. Sternesjo, and
N. Welsh.
Role of cytokines in regulation of pancreatic -cell function.
Biochem. Soc. Trans.
22:26-30 (1994)[Medline].
|
| 13. |
Southern, C.,
D. Schulster, and
I. C. Green.
Inhibition of insulin secretion by interleukin-1 and tumor necrosis factor- via an L-arginine-dependent nitric oxide generation mechanism.
FEBS Lett.
276:42-44 (1990)[Medline].
|
| 14. | McDaniel, M. L., J. R. Colca, N. Kotagal, and P. E. Lacy. A subcellular fractionation approach for studying insulin release mechanisms and calcium metabolism in islets of Langerhans. Methods Enzymol. 98:182-200 (1983)[Medline]. |
| 15. | Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126:131-138 (1982)[Medline]. |
| 16. | Flanagan, W. M., B. Corthesy, R. J. Bram, and G. R. Crabtree. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin. Nature (Lond.) 352:803-807 (1991)[Medline]. |
| 17. | Sen, R. and D. Baltimore. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-716 (1986)[Medline]. |
| 18. | Springer, T. A. Guanidinium methods for total RNA preparation, in Current Protocols in Molecular Biology (F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K. Struhl, eds.). Green Publishing Associates and Wiley-Interscience, New York, 4.2.1-4.2.6 (1991). |
| 19. |
Burd, P. R.,
H. W. Rogers,
J. R. Gordon,
C. A. Martin,
S. Jayaraman,
S. D. Wilson,
A. M. Dvorak,
S. J. Galli, and
M. E. Dorf.
Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines.
J. Exp. Med.
170:245-257 (1989) |
| 20. | Springer, T. A. Purification of proteins by precipitation, in Current Protocols in Molecular Biology (F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K. Struhl, eds.). Green Publishing Associates and Wiley-Interscience, New York, 10.16.1-10.16.9 (1991). |
| 21. |
Corbett, J. A.,
G. Kwon,
J. Turk, and
M. L. McDaniel.
IL-1![]() induces the co-expression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide.
Biochemistry
32:13767-13770 (1993)[Medline].
|
| 22. |
Kwon, G.,
J. A. Corbett,
C. P. Rodi,
P. Sullivan, and
M. L. McDaniel.
IL-1![]() -induced nitric oxide synthase expression by rat pancreatic -cells: evidence for the involvement of NF B in the signaling mechanism.
Endocrinology
136:4790-4795 (1995)[Abstract].
|
| 23. |
Xie, Q.-W.,
Y. Kashiwabara, and
C. Nathan.
Role of transcription factor NF B/Rel in induction of nitric oxide synthase.
J. Biol. Chem.
269:4705-4708 (1994) |
| 24. | Kwon, G., J. A. Corbett, and M. L. McDaniel. Interleukin-1-induced Fos and Jun do not regulate inducible nitric oxide synthase in rat islets of Langerhans and RINm5F cells. Endocrinology 137:825-830 (1996)[Abstract]. |
| 25. |
Farivar, R. S.,
A. V. Chobanian, and
P. Brecher.
Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts.
Circ. Res.
78:759-768 (1996) |
| 26. | Kepka-Lenhart, D., C. Li-Chun, J. Morris, and S. M. Novel. actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. J. Leukoc. Biol. 59:840-846 (1996)[Abstract]. |
| 27. |
Amin, A. R.,
P. Vyas,
M. Attur,
J. Leszczynaka-Piziak,
I. R. Patel,
G. Weissmann, and
S. B. Abramson.
The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase.
Proc. Natl. Acad. Sci. USA
92:7926-7930 (1995) |
| 28. |
Frantz, B. and
E. A. O'Neill.
The effect of sodium salicylate and aspirin on NF B.
Science (Washington D. C.)
270:2017-2018 (1995) |
This article has been cited by other articles:
![]() |
J.-M. Fernandez-Real, A. Lopez-Bermejo, A.-B. Ropero, S. Piquer, A. Nadal, J. Bassols, R. Casamitjana, R. Gomis, E. Arnaiz, I. Perez, et al. Salicylates Increase Insulin Secretion in Healthy Obese Subjects J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2523 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Silva, D. Wang, A. A. Komar, B. A. Castilho, and B. R. G. Williams Salicylates Trigger Protein Synthesis Inhibition in a Protein Kinase R-like Endoplasmic Reticulum Kinase-dependent Manner J. Biol. Chem., April 6, 2007; 282(14): 10164 - 10171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dey, D. Ribnicky, A. G. Kurmukov, and I. Raskin In Vitro and in Vivo Anti-Inflammatory Activity of a Seed Preparation Containing Phenethylisothiocyanate J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 326 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Heitmeier, C. B. Kelly, N. J. Ensor, K. A. Gibson, K. G. Mullis, J. A. Corbett, and T. J. Maziasz Role of Cyclooxygenase-2 in Cytokine-induced {beta}-Cell Dysfunction and Damage by Isolated Rat and Human Islets J. Biol. Chem., December 17, 2004; 279(51): 53145 - 53151. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. O. T. Tran, C. E. Gleason, and R. P. Robertson Inhibition of Interleukin-1{beta}-Induced COX-2 and EP3 Gene Expression by Sodium Salicylate Enhances Pancreatic Islet {beta}-Cell Function Diabetes, June 1, 2002; 51(6): 1772 - 1778. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Katsuyama, M. Shichiri, H. Kato, T. Imai, F. Marumo, and Y. Hirata Differential Inhibitory Actions by Glucocorticoid and Aspirin on Cytokine-Induced Nitric Oxide Production in Vascular Smooth Muscle Cells Endocrinology, May 1, 1999; 140(5): 2183 - 2190. [Abstract] [Full Text] |
||||
![]() |
S. Oberle, T. Polte, A. Abate, H.-P. Podhaisky, and H. Schroder Aspirin Increases Ferritin Synthesis in Endothelial Cells : A Novel Antioxidant Pathway Circ. Res., May 19, 1998; 82(9): 1016 - 1020. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||